The need for highly effective vaccines that induce robust and long-lasting immunity has
never been more apparent. However, for reasons that are still poorly understood, immune …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Develo** an …

Background Stalled progress in controlling Plasmodium falciparum malaria highlights the
need for an effective and deployable vaccine. RTS, S/AS01, the most effective malaria …

Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Executive summary 50 years after a noble but flawed attempt to eradicate malaria in the mid-
20th century, the global malaria community is once again seriously considering eradication …

Despite the overwhelming success of vaccines in preventing infectious diseases, there
remain numerous globally devastating diseases without fully protective vaccines, particularly …

Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by
enhancing antigen presentation to antigen-specific immune cells with the aim to confer long …

Abstract The World Malaria Report, released in December 2021, reflects the unique
challenges currently facing the global malaria community. The report showed the …